References
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021.
- Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225–30. doi:https://doi.org/10.1200/JCO.2016.69.4638.
- Moore KN, Martin LP, O’Malley DM, Matulonis UA, Konner JA, Perez RP, et al. Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a phase i expansion study. J Clin Oncol. 2017;35(10):1112–8. doi:https://doi.org/10.1200/JCO.2016.69.9538.
- Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491–505. doi:https://doi.org/10.1016/S0140-6736(05)67063-8.
- Lewin SN, Herzog TJ, Medel NIB, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 international federation of gynecology and Obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141–9.
- Creasman WT, Odicino F, Maisonneuve P, Beller U, Benedet JL, Heintz APM, et al. Carcinoma of the corpus uteri. Int J Gynecol Obstet. 2003;83(S1):79–118. doi:https://doi.org/10.1016/S0020-7292(03)90116-0.
- Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev. 2010;(12):CD007926.
- Board PDQATE. Endometrial Cancer Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002.
- Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract. 2017;4(19):19.
- Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73.
- Bellone S, Centritto F, Black J, Schwab C, English D, Cocco E, et al. Polymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. Gynecol Oncol. 2015;138(1):11–7. doi:https://doi.org/10.1016/j.ygyno.2015.04.027.
- Kato M, Takano M, Miyamoto M, Sasaki N, Goto T, Tsuda H, et al. DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. J Gynecol Oncol. 2015;26(1):40–5. doi:https://doi.org/10.3802/jgo.2015.26.1.40.
- Muenst S, Soysal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets. 2015;19(2):201–11. doi:https://doi.org/10.1517/14728222.2014.980235.
- Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer. 2017;117(1):1–7. doi:https://doi.org/10.1038/bjc.2017.136.
- Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncoimmunology. 2017;6(2):e1264565. doi:https://doi.org/10.1080/2162402X.2016.1264565.
- Sugiura D, Maruhashi T, Okazaki I-M, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364(6440):558–66. doi:https://doi.org/10.1126/science.aav7062.
- Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35(22):2535–41. doi:https://doi.org/10.1200/JCO.2017.72.5952.
- Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:1–7.
- Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712–6. doi:https://doi.org/10.1046/j.1445-2197.2003.02748.x.
- Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol. 2019;5(8):1141. doi:https://doi.org/10.1001/jamaoncol.2019.1048.
- Fleming GF, Emens LA, Eder JP, Hamilton EP, Liu JF, Liu B, et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced/recurrent endometrial cancer (rEC). JCO. 2017;35(15_suppl):5585. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.5585.
- Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. doi:https://doi.org/10.1126/science.aan6733.
- Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:https://doi.org/10.1200/JCO.19.02105.
- Antill Y, Kok PS, Stockler MR, Robledo K, Yip S, Parry M, et al. LBA12 – updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). Annal Oncol. 2019;30:ix192. doi:https://doi.org/10.1093/annonc/mdz446.011.
- Hasegawa K, Tamura K, Katsumata N, Matsumoto K, Takahashi S, Mukai H, et al. Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers. JCO. 2018;36(15_suppl):5594–5594. doi:https://doi.org/10.1200/JCO.2018.36.15_suppl.5594.
- Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol. 2020;6(11):1766. doi:https://doi.org/10.1001/jamaoncol.2020.4515.
- Garcia C, Ring KL. The role of PD-1 checkpoint inhibition in gynecologic malignancies. Curr Treat Options Oncol. 2018;19(12):70.
- Drakes ML, Czerlanis CM, Stiff PJ. Immune checkpoint blockade in gynecologic cancers: state of affairs. Cancers. 2020;12(11):3301. doi:https://doi.org/10.3390/cancers12113301.
- Oaknin A, León-Castillo A, Lorusso D. Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives. Curr Opin Oncol. 2020;32(5):471–80. doi:https://doi.org/10.1097/CCO.0000000000000658.
- Petrelli F, Ghidini M, Ghidini A, Tomasello G. Outcomes following immune checkpoint inhibitor treatment of patients with microsatellite instability-high cancers: a systematic review and meta-analysis. JAMA Oncol. 2020;6(7):1068–71. doi:https://doi.org/10.1001/jamaoncol.2020.1046.
- Lee V, Murphy A, Le DT, Diaz LA. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21(10):1200–11. doi:https://doi.org/10.1634/theoncologist.2016-0046.
- Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. doi:https://doi.org/10.1056/NEJMoa1500596.
- Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019;30(7):1096–103. doi:https://doi.org/10.1093/annonc/mdz134.
- Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396.
- Ghose A, Moschetta M, Pappas-Gogos G, Sheriff M, Boussios S. Genetic aberrations of DNA repair pathways in prostate cancer: translation to the clinic. Int J Mol Sci. 2021;22(18).
- Barata P, Agarwal N, Nussenzveig R, Gerendash B, Jaeger E, Hatton W, et al. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. J Immunother Cancer. 2020;8(2):e001065. doi:https://doi.org/10.1136/jitc-2020-001065.
- Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, et al. Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade. JAMA Oncol. 2019;5(4):471–8. doi:https://doi.org/10.1001/jamaoncol.2018.5801.
- Pietrantonio F, Randon G, Di Bartolomeo M, Luciani A, Chao J, Smyth EC, et al. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6(1):100036. doi:https://doi.org/10.1016/j.esmoop.2020.100036.
- Diaz-Padilla I, Romero N, Amir E, Matias-Guiu X, Vilar E, Muggia F, et al. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2013;88(1):154–67. doi:https://doi.org/10.1016/j.critrevonc.2013.03.002.
- Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38(26):2981–92. doi:https://doi.org/10.1200/JCO.19.02627.
- Peng L, Qin B-D, Xiao K, Xu S, Yang J-S, Zang Y-S, et al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy. Oncoimmunology. 2020;9(1):1781333. doi:https://doi.org/10.1080/2162402X.2020.1781333.
- Chabanon RM, Rouanne M, Lord CJ, Soria J-C, Pasero P, Postel-Vinay S. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat Rev Cancer. 2021;21(11):701–17. doi:https://doi.org/10.1038/s41568-021-00386-6.
- Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–23. doi:https://doi.org/10.1001/jamaoncol.2015.2151.
- Pilié PG, Gay CM, Byers LA, O’Connor MJ, Yap TA. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin Cancer Res. 2019;25(13):3759–71. doi:https://doi.org/10.1158/1078-0432.CCR-18-0968.
- Demircan NC, Boussios S, Tasci T, Öztürk MA. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med. 2020;8(24):1714. doi:https://doi.org/10.21037/atm-20-4499.
- Färkkilä A, Gulhan DC, Casado J, Jacobson CA, Nguyen H, Kochupurakkal B, et al. Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020;11(1):1459. doi:https://doi.org/10.1038/s41467-020-15315-8.
- Smith ES, Da Cruz Paula A, Cadoo KA, Abu-Rustum NR, Pei X, Brown DN, et al. Endometrial cancers in or germline mutation carriers: assessment of homologous recombination DNA repair defects. JCO Precis Oncol. 2019;3(3):1–11. doi:https://doi.org/10.1200/PO.19.00103.
- Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N. Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opin Ther Targets. 2021;25(5):329–33. doi:https://doi.org/10.1080/14728222.2021.1951226.
- Boussios S, Mikropoulos C, Samartzis E, Karihtala P, Moschetta M, Sheriff M, et al. Wise management of ovarian cancer: on the cutting edge. J Pers Med. 2020;10(2):41.
- Jiao S, Xia W, Yamaguchi H, Wei Y, Chen M-K, Hsu J-M, et al. PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res. 2017;23(14):3711–20. doi:https://doi.org/10.1158/1078-0432.CCR-16-3215.
- Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:https://doi.org/10.1016/j.ccell.2015.10.012.
- Apetoh L, Ladoire S, Coukos G, Ghiringhelli F. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? Ann Oncol. 2015;26(9):1813–23. doi:https://doi.org/10.1093/annonc/mdv209.
- Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151–60. doi:https://doi.org/10.1038/nrclinonc.2010.223.
- Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 2011;30(1):61–9. doi:https://doi.org/10.1007/s10555-011-9273-4.
- Rubinstein MM, Caird I, Zhou Q, Iasonos A, Friedman CF, Cadoo KA, et al. A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma. JCO. 2019;37(15_suppl):5582–5582. doi:https://doi.org/10.1200/JCO.2019.37.15_suppl.5582.
- Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–7. doi:https://doi.org/10.1038/nature14292.
- Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005;63(3):655–66. doi:https://doi.org/10.1016/j.ijrobp.2005.06.032.
- Levy A, Chargari C, Cheminant M, Simon N, Bourgier C, Deutsch E. Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol Hematol. 2013;85(3):278–87. doi:https://doi.org/10.1016/j.critrevonc.2012.09.001.
- Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16(13):e498–e509. doi:https://doi.org/10.1016/S1470-2045(15)00007-8.
- US National Library of Medicine, Clinical Trials.gov Database Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) [cited 2021 April 6]. Available from: https://clinicaltrials.gov/ct2/results?recrs=&cond=Endometrial+Cancer&term=Avelumab&cntry=&state=&city=&dist=
- US National Library of Medicine, Clinical Trials.gov Database Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) [cited 2021 April 6]. Available from: https://clinicaltrials.gov/ct2/results?recrs=&cond=Endometrial+Cancer&term=Atezolizumab&cntry=&state=&city=&dist=
- US National Library of Medicine, Clinical Trials.gov Database Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) [cited 2021 April 6]. Available from: https://clinicaltrials.gov/ct2/results?cond=Endometrial+Cancer&term=Durvalumab&cntry=&state=&city=&dist=&Search=%E6%90%9C%E7%B4%A2
- US National Library of Medicine, Clinical Trials.gov Database Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) [cited 2021 April 6]. Available from: https://clinicaltrials.gov/ct2/results?cond=Endometrial+Cancer&term=Nivolumab&cntry=&state=&city=&dist=&Search=%E6%90%9C%E7%B4%A2
- US National Library of Medicine, Clinical Trials.gov Database Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) [cited 2021 April 6]. Available from: https://clinicaltrials.gov/ct2/results?cond=Endometrial+Cancer&term=Pembrolizumab&cntry=&state=&city=&dist=&Search=%E6%90%9C%E7%B4%A2